The recommended dose of Quviviq improved sleep maintenance. Credit: Gregory Pappas on Unsplash.

Idorsia has received marketing authorisation from Health Canada for Quviviq (daridorexant) to manage insomnia in adult patients.

The dual orexin receptor antagonist (DORA) Quviviq acts on orexin 1 and orexin 2 receptors equipotently.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It blocks only the orexin receptors activation that promote wakefulness, rather than inducing sleep through broad inhibition of brain activity (sedation).

This therapy decreases the over-active wake drive for patients with insomnia and allows sleep to occur, without interfering with the stages of sleep.

The regulator recommended one Quviviq 50mg oral tablet each night, taken 30 minutes before going to bed with a minimum of seven hours remaining before planned awakening.

Idorsia noted that some patients may take 25mg once each night.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Idorsia managing director and CEO Jean-Paul Clozel stated: “I’m very pleased with the positive decision from Health Canada, particularly seeing the recommended dose of 50mg, which we know works best.

“It is estimated that 8.8% of adults in Canada suffer from chronic insomnia, which we know takes its toll on their physical and mental health.

“Sleep is one of the key pillars of health, so for these patients the regular nightly use of Quviviq can have a big impact on both their night’s sleep and their daily life.”

The regulatory decision is supported by the data obtained from Phase III clinical trials and a long-term follow-up extension study.

The findings showed that the recommended dose of Quviviq improved sleep maintenance and sleep onset, as well as self-reported total sleep time in adults with insomnia.